NIH, CDC Distributing OTC COVID-19 Tests In US Study On Reducing Community Transmission

NIH pays for 2 million Quidel QuickVue tests in a program it is conducting with the CDC to determine whether frequent self-administered testing helps reduce community transmission of SARS-CoV-2.

A COVID-19 test recently cleared for over-the-counter (OTC) sales in the US will do more than expand consumer access to tests for infections.

The National Institutes of Health is paying for 2 million Quidel QuickVue At-Home tests to use in a program...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

INBRAIN, Mayo Clinic To Test BCI With Standard Deep Brain Stimulation In Parkinson’s Patients

Barcelona-based INBRAIN Neuroelectronics is partnering with Mayo Clinic to test whether its graphene-based cortical brain computer interface can enhance standard DBS in Parkinson’s, aiming for more precise adaptive therapy and improved gait outcomes.

New Guidelines Support Early Intervention With Edwards TAVR Device Sapien

 

The new ESC and EACTS guidelines allow aortic stenosis patients without symptoms to be considered for a transcatheter aortic valve replacement. The move opens the market for Edwards Lifesciences, the only medtech with a Europe and US-approved device for asymptomatic severe aortic stenosis.

LSX Panel Takes On Present And Future Of Neurotech

 
• By 

A Sept. 17 panel at LSX in Boston discussed how brain-computer interface devices (BCIs) work, potential applications for BCIs, partnership, the investment landscape, ethical considerations and the five to 10-year outlook for the neurotech sector.

Breast Tissue Regeneration: Tensive’s Journey To Restore ‘Wholeness’ For Cancer Survivors

 

Medtech Insight spoke with Sanjay Kakkar, Tensive CEO, about the firm’s breast tissue regeneration implant and its surgical benefits, including a reduced operation time of 74 minutes. He anticipates regulatory approval for Regenera in early 2027.

More from Business

Mendaera’s Handheld Robotic System Poised To ‘Transform Needle-Based Procedures’ Starting In Urology

 
• By 

After receiving US FDA clearance and reporting first successful use at Mayo Clinic, the Silicon Valley start-up plans to partner with leading centers to transform needle-based procedures with its robotic system starting with urology, then expand into other specialties, the CEO said.

Asabys Partners Talks SafeHeal €10M Investment At LSI Europe

 

SafeHeal has secured an additional €10m for its Colovac device, bringing its total funding to €97.5m. Led by Asabys Partners, this funding offers both economic and clinical benefits, potentially reducing costs and complications associated with temporary stomas.

Doug Godshall Takes Helm At Galvanize As $100M Round Fuels Next Phase Of PEF Development

 
• By 

Galvanize will use its $100m Series C funding to expand commercial operations and advance Aliya PEF in oncology and RheOx in chronic bronchitis, while continuing to refine its nonthermal PEF platform, which delivers short electrical pulses to disrupt disease processes.